Similar articles

• Combined treatment of parkinsonism with L-dopa and amantadine.

  Godwin-Austen RB, Frears CC, Bergmann S, Parkes JD, Knill-Jones RP. Godwin-Austen RB, et al. Lancet. 1970 Aug 22;2(7669):383-5. doi: 10.1016/s0140-6736(70)90002-4. Lancet. 1970. PMID: 4194690 Clinical Trial. No abstract available.
• L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.

  Reveno WS, Bauer RB, Rosenbaum H. Reveno WS, et al. Geriatrics. 1971 Aug;26(8):61-70. Geriatrics. 1971. PMID: 5096462 No abstract available.
• Recent advances in the treatment of Parkinsonism with drugs.

  Rinne UK. Rinne UK. Acta Neurol Scand Suppl. 1972;51:59-103. Acta Neurol Scand Suppl. 1972. PMID: 4576076 Review. No abstract available.
• [Parkinsonism. Therapeutic, pathophysiological, pharmacological and biochemical aspects].

  Dupont E. Dupont E. Ugeskr Laeger. 1973 Jan 15;135(3):116-22. Ugeskr Laeger. 1973. PMID: 4567942 Review. Danish. No abstract available.
• Therapeutic uses and side effects of L-dopa.

  Boshes B. Boshes B. Adv Intern Med. 1972;18:219-49. Adv Intern Med. 1972. PMID: 4576081 Review. No abstract available.